Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ligand Pharmaceuticals (LGND) Revenue (2016 - 2025)

Ligand Pharmaceuticals' Revenue history spans 16 years, with the latest figure at $59.7 million for Q4 2025.

  • For Q4 2025, Revenue rose 39.37% year-over-year to $59.7 million; the TTM value through Dec 2025 reached $268.1 million, up 60.4%, while the annual FY2025 figure was $268.1 million, 60.4% up from the prior year.
  • Revenue for Q4 2025 was $59.7 million at Ligand Pharmaceuticals, down from $115.5 million in the prior quarter.
  • Across five years, Revenue topped out at $115.5 million in Q3 2025 and bottomed at $26.4 million in Q2 2023.
  • The 5-year median for Revenue is $47.1 million (2021), against an average of $50.2 million.
  • The largest annual shift saw Revenue crashed 47.4% in 2023 before it soared 122.85% in 2025.
  • A 5-year view of Revenue shows it stood at $56.4 million in 2021, then dropped by 10.68% to $50.4 million in 2022, then tumbled by 44.22% to $28.1 million in 2023, then surged by 52.35% to $42.8 million in 2024, then surged by 39.37% to $59.7 million in 2025.
  • Per Business Quant, the three most recent readings for LGND's Revenue are $59.7 million (Q4 2025), $115.5 million (Q3 2025), and $47.6 million (Q2 2025).